Algernon Health Inc. closes the second tranche of its non-brokered private placement, raising CAD $210,000 from the sale of 3,000,000 units at CAD $0.07 per Unit. The funds will be used to advance its Alzheimer’s Disease program, open its first U.S. AD clinic, cover general expenses, and for working capital. The securities issued will be subject to a hold period of four months plus a day. The Company did not pay any cash finder’s fees for this tranche. For more information, contact CEO Christopher J. Moreau at [email protected]. Algernon Health focuses on brain optimized PET scanning services in North America for early-stage Alzheimer’s Disease detection.

Read more at GlobeNewswire: Algernon Closes Second Tranche of Private Placement